03/19/2025
ALLAN GOBBS – LEADING INVESTOR IN LIFE SCIENCES, CEO & STRATEGIC ADVISOR
Allan Gobbs is the Managing Partner at ATEM Capital, a New York-based venture firm specializing in Life Sciences investments. Over the past few years, he has successfully guided five portfolio companies to IPOs on NASDAQ, including Atea Pharmaceuticals, Marinus Pharmaceuticals, and Syndax Pharmaceuticals. Additionally, four of his portfolio companies have been acquired, among them:
— Tobira Therapeutics, acquired by Allergan for up to $1.7 billion
— Amolyt Pharmaceuticals, an AI-powered peptide drug discovery company, acquired by AstraZeneca for up to $1.05 billion in July 2024
Beyond venture investments, Allan plays a key role in driving innovation across biotech and healthtech sectors:
— CEO & Chairman of YCare, a digital health integrator in partnership with Dell Technologies and InterSystems
— Chairman of PGxAI, an AI-driven pharmacogenetics platform
— President of Virry Health, an AI-powered XR platform tackling mental health conditions
Before co-founding ATEM Capital, Allan worked as an investment banker at Barclays Capital, advising on M&A and capital market transactions worth over $20 billion. He is also actively involved in industry leadership, serving as:
— Member of the Forbes Business Council
— Member of the Private Directors Association
— Review Committee Member at the National Cancer Institute (NIH)
With deep expertise in venture investing, AI-driven healthcare, and biotechnology, Allan is dedicated to empowering the next generation of investors and founders.
🔥 Join Allan in the exclusive 8-session program to master the strategies behind investing and building transformative ventures.
03/19/2025